S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
EU migration impasse leaves many refugees out in the cold
NASDAQ:ARGX

argenx - ARGX Stock Forecast, Price & News

$370.95
-1.32 (-0.35%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$370.00
$373.83
50-Day Range
$369.42
$403.65
52-Week Range
$256.44
$407.93
Volume
206,480 shs
Average Volume
212,545 shs
Market Capitalization
$20.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$453.23

argenx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
22.2% Upside
$453.23 Price Target
Short Interest
Healthy
1.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of argenx in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($15.54) to ($9.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

341st out of 1,028 stocks

Biological Products, Except Diagnostic Industry

59th out of 168 stocks

ARGX stock logo

About argenx (NASDAQ:ARGX) Stock

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

argenx SE (NASDAQ:ARGX) Sees Large Decline in Short Interest
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Cowen Increases argenx (NASDAQ:ARGX) Price Target to $458.00
Analysts Set argenx SE (NASDAQ:ARGX) Price Target at $452.18
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
argenx Appoints Ana Cespedes to Board of Directors
Argenx To Acquire FDA Priority Review Voucher - Quick Facts
Should You Invest in argenx SE (ARGX)?
Why Earnings Season Could Be Great for argenx (ARGX)
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Company Calendar

Last Earnings
10/27/2021
Today
2/05/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$453.23
High Stock Price Forecast
$480.00
Low Stock Price Forecast
$420.00
Forecasted Upside/Downside
+22.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

Net Income
$-408,270,000.00
Net Margins
-295.08%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$539.42 million
Book Value
$49.05 per share

Miscellaneous

Free Float
54,050,000
Market Cap
$20.55 billion
Optionable
Optionable
Beta
0.73

Key Executives

  • Tim van Hauwermeiren
    Chief Executive Officer & Executive Director
  • R. Keith Woods
    Chief Operating Officer
  • Karl Gubitz
    Chief Financial Officer
  • Hans J. W. de Haard
    Chief Scientific Officer
  • Luc Truyen
    Chief Medical Officer













ARGX Stock - Frequently Asked Questions

Should I buy or sell argenx stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price forecast for 2023?

15 Wall Street research analysts have issued 12-month price targets for argenx's shares. Their ARGX share price forecasts range from $420.00 to $480.00. On average, they predict the company's share price to reach $453.23 in the next year. This suggests a possible upside of 22.2% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2023?

argenx's stock was trading at $378.83 at the start of the year. Since then, ARGX shares have decreased by 2.1% and is now trading at $370.95.
View the best growth stocks for 2023 here
.

Are investors shorting argenx?

argenx saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 777,900 shares, a decrease of 6.7% from the December 31st total of 834,000 shares. Based on an average daily trading volume, of 252,000 shares, the short-interest ratio is presently 3.1 days.
View argenx's Short Interest
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings results on Wednesday, October, 27th. The company reported ($4.10) earnings per share for the quarter, topping the consensus estimate of ($4.48) by $0.38. The business earned $7.11 million during the quarter, compared to the consensus estimate of $20 million. argenx had a negative net margin of 295.08% and a negative trailing twelve-month return on equity of 66.04%. During the same period in the previous year, the company posted ($3.96) EPS.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.24%), New York State Common Retirement Fund (0.21%), Allspring Global Investments Holdings LLC (0.13%), Bank of Montreal Can (0.12%), Tobam (0.05%) and Mckinley Capital Management LLC Delaware (0.04%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $370.95.

How much money does argenx make?

argenx (NASDAQ:ARGX) has a market capitalization of $20.55 billion and generates $262.61 million in revenue each year. The company earns $-408,270,000.00 in net income (profit) each year or ($17.19) on an earnings per share basis.

How many employees does argenx have?

The company employs 650 workers across the globe.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 2/5/2023 by MarketBeat.com Staff